Gilead Sciences (GILD) Income from Non-Controlling Interests (2009 - 2023)

Gilead Sciences (GILD) posted Income from Non-Controlling Interests of -$12.0 million for Q4 2023, down 50.0% quarter-over-quarter from -$8.0 million in Q3 2023, and down 71.43% year-on-year from -$42.0 million in Q4 2022.

Gilead Sciences (GILD) Income from Non-Controlling Interests (2009 - 2023) Analysis & Trends

Gilead Sciences (GILD) has reported Income from Non-Controlling Interests for 15 consecutive years, with -$12.0 million the latest figure, recorded in Q4 2023.

  • Income from Non-Controlling Interests for Q4 2023 came in at -$12.0 million, down 71.43% year-over-year; the trailing twelve-month figure through Sep 2024 was -$12.0 million (up 74.47% YoY), and the FY2023 annual result was -$52.0 million, down 100.0% from the prior year.
  • Income from Non-Controlling Interests was -$12.0 million for Q4 2023 at Gilead Sciences, down from -$8.0 million in the prior quarter.
  • Over five years, Income from Non-Controlling Interests peaked at -$3.0 million in Q3 2019 and troughed at -$26.0 million in Q1 2023.
  • Average Income from Non-Controlling Interests over 5 years is -$7.9 million, with a median of -$7.0 million recorded in 2019.
  • Year-over-year, Income from Non-Controlling Interests slumped 800.0% in 2019 and soared 50.0% in 2022.
  • Over 5 years, Income from Non-Controlling Interests stood at -$7.0 million in 2019, then changed by 0.0% to -$7.0 million in 2020, then advanced by 14.29% to -$6.0 million in 2021, then slipped by 16.67% to -$7.0 million in 2022, then plunged by 71.43% to -$12.0 million in 2023.
  • Per Business Quant data, the three most recent Income from Non-Controlling Interests figures were -$12.0 million in Q4 2023, -$8.0 million in Q3 2023, and -$6.0 million in Q2 2023.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Inc. Minority (Qtr)
1 Eli Lilly 1,066.16 Bn 1,060.88 Bn 16.22 Bn -
2 Johnson & Johnson 611.69 Bn 589.64 Bn 15.96 Bn -
3 AbbVie 444.34 Bn 434.99 Bn 10.78 Bn 2.00 Mn
4 Astrazeneca 284.94 Bn 277.05 Bn 12.61 Bn 1.00 Mn
5 Merck 224.23 Bn 218.58 Bn 12.09 Bn -3.00 Mn
6 Amgen 195.12 Bn 183.08 Bn 5.87 Bn -
7 Gilead Sciences 156.45 Bn 148.73 Bn 5.52 Bn -
8 Pfizer 136.01 Bn 123.24 Bn -1.21 Bn 8.00 Mn
9 Novartis Ag 113.45 Bn 113.67 Bn - -
10 Biogen 30.87 Bn 26.59 Bn 1.82 Bn -

Historic Data

Download Data
DateValue
Dec 31, 2023 -12.00 Mn
Sep 30, 2023 -8.00 Mn
Jun 30, 2023 -6.00 Mn
Mar 31, 2023 -26.00 Mn
Dec 31, 2022 -7.00 Mn
Sep 30, 2022 -3.00 Mn
Jun 30, 2022 -9.00 Mn
Mar 31, 2022 -7.00 Mn
Dec 31, 2021 -6.00 Mn
Sep 30, 2021 -6.00 Mn
Jun 30, 2021 -5.00 Mn
Mar 31, 2021 -7.00 Mn
Dec 31, 2020 -7.00 Mn
Sep 30, 2020 -7.00 Mn
Jun 30, 2020 -7.00 Mn
Mar 31, 2020 -13.00 Mn
Dec 31, 2019 -7.00 Mn
Sep 30, 2019 -3.00 Mn
Jun 30, 2019 -5.00 Mn
Mar 31, 2019 -7.00 Mn